treatment-related adverse events

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The ABFM regimen in AYA patients caused significant asparaginase-related toxicities including grade 3-4 hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, thrombosis in 19%, and severe a

Effect: adverse; Grade 3-4 liver enzyme elevations in 41%

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse

The hyper-CVAD regimen was associated with myelosuppression-related complications as its predominant toxicity profile, distinct from the asparaginase-related toxicities seen with ABFM.

Effect: adverse